LT5001 / Lumosa Therap - LARVOL DELTA

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients (clinicaltrials.gov) - P1/2 | N=18 | Terminated | Sponsor: Lumosa Therapeutics Co., Ltd. | N=78 ➔ 18 | Unknown status ➔ Terminated; Change in the clinical development plan

Enrollment change • Trial termination • Dermatology • Pruritus • Renal Disease

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients (clinicaltrials.gov) - P1/2; N=78; Recruiting; Sponsor: Lumosa Therapeutics Co., Ltd.

Clinical • New P1/2 trial • Dermatology • Pruritus • Renal Disease